Core Insights - The Shanghai Municipal Government has released the "Three-Year Action Plan to Support the Transformation and Upgrading of Advanced Manufacturing (2026-2028)", aiming to build a modern industrial system centered on advanced manufacturing [1] - The plan targets the addition of 100 manufacturing enterprises with an annual output value exceeding 1 billion yuan by 2028, bringing the total to over 600 [1] - The initiative aims to drive the addition of 500 industrial enterprises above designated size in the supply chain and significantly increase the proportion of R&D expenses in revenue for manufacturing enterprises [1] Group 1: Structural Upgrading - The plan emphasizes a multi-dimensional industrial upgrade matrix, accelerating iterations in traditional advantageous industries [1] - Specific strategies include petrochemical companies shifting towards new functional materials, steel companies enhancing specialty steel production, and light industry companies creating trendy domestic products [1] - Leading industries will focus on breakthroughs in the integrated circuit industry chain, biomedicine innovation, and intelligent computing chip development, fostering international leading enterprises [1] Group 2: Emerging Industries - The plan promotes simultaneous development of key and emerging industries, including the growth of six major sectors such as next-generation electronic information and smart connected new energy vehicles [1] - New fields like low-altitude economy and commercial aerospace will be explored, with a focus on scaling products like eVTOL and humanoid robots [1] Group 3: Innovation and Incentives - The plan introduces significant incentive policies for core technology breakthroughs, focusing on frontier technologies such as laser manufacturing and quantum technology [2] - Key links in the industrial chain, including integrated circuits and large aircraft, will be prioritized for technological advancements [2] Group 4: Digital and Green Transformation - The "Action for Upgrading Capability and Quality" outlines a transformation path, implementing "AI + Manufacturing" initiatives for digital transformation [2] - By 2027, large enterprises are expected to achieve full coverage of digital applications, with the goal of establishing fully intelligent factories by 2028, achieving a robot density of 600 units per 10,000 people [2] - In terms of green transformation, the plan aims to add over 100 national-level green factories [2]

Group 1 - The core viewpoint emphasizes the importance of policy support and reform innovation in achieving economic stability and growth in 2025, with a GDP growth of 5.2% in the first three quarters and an expected annual growth rate of around 5% [1][2] - The economic structure is continuously optimizing, with emerging industries like artificial intelligence and biomedicine thriving, and significant sales driven by the "two new" policies, including over 2.5 trillion yuan in sales from consumer goods replacement [1][3] - Industrial enterprises have seen a profit increase of 1.9% from January to October 2025, indicating improved corporate performance despite ongoing challenges [1][3] Group 2 - Current economic challenges include insufficient effective demand, with investment showing negative growth and overall consumption remaining weak [2][3] - Price levels are low, with the Consumer Price Index (CPI) fluctuating around zero for two consecutive years and the Producer Price Index (PPI) experiencing negative growth for three years [3][4] - Employment and resident income growth face significant pressure, as highlighted in the "15th Five-Year Plan," indicating a need for focused policy measures [3][4] Group 3 - The central economic work conference has called for more proactive macroeconomic policies to address the ongoing economic downward pressure, including maintaining necessary fiscal deficits and increasing central budget investments [5][6] - A moderately loose monetary policy is to be implemented, focusing on stabilizing economic growth and ensuring reasonable price recovery, with tools like reserve requirement ratio cuts and interest rate reductions [6][7] - The conference outlined "eight persistences" for economic work, emphasizing the need for deep reforms alongside policy support to enhance domestic demand and improve income distribution [7][8]

科创100ETF基金紧密跟踪上证科创板100指数，上证科创板100指数从上海证券交易所科创板中选取市 值中等且流动性较好的100只证券作为样本。上证科创板100指数与上证科创板50成份指数共同构成上证 科创板规模指数系列，反映科创板市场不同市值规模上市公司证券的整体表现。 数据显示，截至2025年12月31日，上证科创板100指数(000698)前十大权重股分别为华虹公司、东芯股 份、源杰科技、睿创微纳、中科飞测、国盾量子、百济神州、仕佳光子、复旦微电、安集科技，前十大 权重股合计占比26.21%。 科创100ETF基金(588220)，场外联接(A：019861；C：019862；I：022845)。 AI应用、AI医疗表现活跃，消息面上，英伟达将在未来五年内与礼来共同投资10亿美元建立人工智能 药物实验室。英伟达和礼来将率先推动机器人技术和物理人工智能，加速和扩大医学发现与生产。此 外，在医药方面，荣昌生物发布公告称，公司与艾伯维就RC148签署独家授权许可协议。在协议批准生 效后，荣昌生物将收到6.5亿美元的首付款，并有资格获得最高达49.5亿美元的开发、监管和商业化里程 碑付款，以及在大中华区以外地区 ...

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has entered into an option and licensing agreement with Yushibo to systematically evaluate the bispecific antibody-drug conjugate (BsADC) projects, aiming to accelerate the development of bispecific antibody-drug conjugates (BsAD2C) [1] Group 1 - The agreement grants Yushibo an option to obtain global exclusive rights to two BsADC projects from Baiaosaitu [1] - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1] - Specific financial terms of the agreement have not been disclosed [1]

Group 1 - The core point of the news is the significant rise in the stock prices of pharmaceutical companies in both A-shares and Hong Kong stocks, driven by the announcement of a major licensing deal between Chinese biopharmaceutical company Rongchang Biopharma and AbbVie, valued at $5.6 billion [1][3] - As of January 13, over 40% of stocks in the A-share biopharmaceutical sector saw price increases, with notable gains from companies like Kanglaweishi, Hongbo Pharmaceutical, and Rongchang Biopharma, which all experienced rises exceeding 15% [1] - In the Hong Kong market, more than half of the healthcare stocks also rose, with companies such as WuXi AppTec and Cornerstone Pharmaceuticals seeing increases over 8% [1] Group 2 - The annual J.P. Morgan Global Healthcare Conference is taking place in San Francisco, focusing on biotechnology and biopharmaceuticals, and is a key event for insights into global pharmaceutical industry trends [3] - The licensing deal between Rongchang Biopharma and AbbVie includes an upfront payment of $650 million, which has positively impacted the stock prices of related dual-antibody concept stocks, such as Yiming Anke and Sangfor Biopharma [3] - The overall index for the A-share pharmaceutical outsourcing (CXO) sector rose over 5% as of January 13, reflecting a strong market response to the licensing news [3][4] Group 3 - WuXi AppTec has raised its revenue forecast for the previous year for the third time, indicating strong performance expectations [4] - WuXi Biologics expressed confidence in maintaining growth momentum through 2026, showcasing optimism for future prospects [5] - CITIC Securities has published a report highlighting the potential for Chinese pharmaceutical companies to achieve technological breakthroughs and international opportunities, marking a shift towards global value creation [6]

近年来，中国人民银行凉山州分行结合凉山州委、州政府打造生物医药产业集群的战略部署，推动金融 资源精准流入重点环节和龙头企业。通过差异化信贷支持、集群式产融协同和创新型金融产品，凉山生 物医药产业加速崛起，为地方经济注入新动能。 围绕生物医药企业不同发展阶段和经营特点，当地金融机构提供差异化信贷支持，精准满足企业从种植 收购、经营周转到基地建设、智能制造等各环节的融资需求。截至目前，全州银行机构已为生物医药企 业提供授信超7.36亿元，发放贷款5.98亿元，贷款加权平均利率仅3.53%，显著低于全州平均水平。工 行凉山分行以信用方式为好医生攀西药业发放流动资金贷款1亿元，利率低至2.42%，有效缓解了企业 的资金压力。 在四川省凉山州西昌生物医药产业园，好医生、新鑫中药、华润三九（000999）等龙头企业正加紧生 产。车间里，自动化设备高速运转，科研人员正进行检测。"这几年金融支持越来越有力，资金能覆盖 种植、加工、研发等环节，让企业敢投入、能扩产。"好医生攀西药业相关负责人对《金融时报》记者 说。 针对生物医药企业轻资产、高研发的特点，中国人民银行凉山州分行鼓励银行创新贷款模式，推广知识 产权质押、科研项目贷 ...

Core Viewpoint - The article highlights the strong performance of pharmaceutical stocks in both A-shares and Hong Kong stocks, driven by the annual J.P. Morgan Global Healthcare Conference, which focuses on biotechnology and biopharmaceuticals, showcasing the growing influence of Chinese innovative drugs in the global market [3][4]. Group 1: Market Performance - As of January 13, over 40% of stocks in the A-share biopharmaceutical sector saw gains, with companies like Kanglaite (920575.BJ) and Hongbo Pharmaceutical (301230.SZ) rising more than 15% [3]. - In the Hong Kong market, more than half of the healthcare stocks experienced increases, with WuXi AppTec (02126.HK) and Hengrui Medicine (02616.HK) seeing gains exceeding 8% [3]. - The overall A-share pharmaceutical outsourcing (CXO) index rose over 5% by mid-morning on January 13 [6]. Group 2: Major Transactions - A significant licensing deal was announced on January 12, where Chinese biopharmaceutical company Rongchang Bio entered a $5.6 billion collaboration with AbbVie, receiving an upfront payment of $650 million [4][5]. - This transaction positively impacted the stock prices of dual-antibody concept stocks, with companies like Yiming Anke (01541.HK) and Sanofi (688336.SH) seeing price increases of over 10% and 4%, respectively [5]. Group 3: Industry Trends - The article notes that the J.P. Morgan conference often leads to increased M&A and licensing activity in the global innovative drug sector, with expectations for new deals to emerge this year [4]. - According to a recent report by CITIC Securities, there is optimism regarding Chinese companies' technological breakthroughs and international opportunities, indicating a shift from a single market focus to global value creation [7]. - Chinese pharmaceutical companies are becoming key players in global drug innovation, leveraging their capabilities to partner with large pharmaceutical and biotech firms, thus enhancing their role in the global market [7].

Core Insights - The "Beijing-Tianjin-Hebei Collaborative Innovation Index (2026)" was released to monitor and evaluate the collaborative innovation development in the region, showing significant growth from 100 in 2013 to 388 in 2024, with an average annual growth rate of 13.1% [1] Group 1: Innovation Index Growth - The index measures collaborative innovation across five dimensions: innovation capability, research cooperation, technology connections, innovation performance, and innovation environment [1] - Beijing's collaborative innovation index saw the largest increase, growing from 657.7 to 1198.4 from 2013 to 2024, indicating strong radiative power [1] Group 2: Regional Performance - Tianjin's collaborative innovation index increased by 14.7% in 2024 compared to 2023, while Hebei maintained a steady growth rate of 13.1% [2] - The gap in innovation indices between Beijing and Hebei has narrowed, while the gap between Beijing and Tianjin has widened [2] Group 3: Industry Collaboration - The three regions have formed a new development pattern characterized by mutual benefits and complementary advantages, leading to breakthroughs in industries, transportation, and environmental sectors [2] - Beijing leads in hydrogen and biomedicine, Tianjin in high-end industrial mother machines and cybersecurity, and Hebei in new energy and intelligent connected vehicles [2] Group 4: Technological Innovation - The technology innovation network in the region is primarily led by Beijing, which accounted for 40.9% of patent cooperation in 2024 [3] - The total value of technology contracts in the region reached 1.3 trillion yuan, representing nearly 20% of the national total [3] Group 5: Innovation Environment - The development of the "Beijing-Tianjin-Hebei on Tracks" initiative has facilitated smoother flow of innovation elements, supported by a combination of policies for high-quality innovation and entrepreneurship [3] - A total of 13 innovation platforms have been established across the three regions, accelerating the incubation and transformation of innovative results [3] Group 6: Future Development Strategies - Strengthening international technological capabilities and building a collaborative innovation network centered around leading technology enterprises is crucial for future development [4] - The strategy includes enhancing original and disruptive technological innovations and fostering a collaborative innovation community in the Beijing-Tianjin-Hebei region [4][5]

凭借平台创新实力与管线潜力，勤浩医药连续获得"姑苏重大创新团队"、"江苏省重大专项"，并参 与"创新药物研发国家科技重大专项"，技术路径与创新价值获多方认可。 此次融资的完成，将进一步加速公司研发进程与战略布局。未来，勤浩医药将依托AI赋能的高效创新 体系，聚焦未被满足的临床需求，携手产学研各界，继续推动具有全球竞争力的创新药开发，为患者带 来突破性治疗方案。 作为自主创新驱动的Biotech公司，勤浩医药始终聚焦于全球领先的靶向抗肿瘤小分子药物开发。公司 构建了"AI/Biology-Driven Smart Design"的药物开发理念，深度融合计算化学、人工智能与内部实验平 台，形成"数据驱动、快速迭代"的高效研发体系，全面赋能从药物发现至临床开发的全流程。 公司已建立涵盖Ras信号通路与合成致死领域的差异化管线，并推动多个全球领先的项目进入临床阶 段，展现了持续创新的能力，也望为难治性肿瘤的精准治疗和联合治疗提供具备国际竞争力的解决方 案。 智通财经APP获悉，1月13日，致力于利用组合技术平台开发全球新一代抗肿瘤小分子药物的研发企业 勤浩医药宣布，已完成超3亿元人民币Crossover轮融资。本轮融 ...

Group 1 - The core point of the news is the significant rise in the pharmaceutical sector in both A-shares and Hong Kong stocks, driven by the annual J.P. Morgan Global Healthcare Conference, which highlights the latest trends and expectations in the biotechnology and biopharmaceutical industries [1][3] - A notable external licensing deal was announced, where Chinese biopharmaceutical company Rongchang Bio entered into a collaboration with AbbVie worth up to $5.6 billion, including an upfront payment of $650 million, which positively impacted the stock prices of related companies [3] - The market is witnessing a surge in stock prices for dual-antibody concept stocks, with companies like Yiming Anke and Sanofi Guojian seeing significant increases of over 10.10% and 4% respectively [3] Group 2 - The external licensing of innovative drugs is becoming a crucial source of financing and revenue for innovative pharmaceutical companies, potentially increasing order volumes for contract research organizations (CROs) [3] - The CRO sector also experienced a price surge, with WuXi AppTec's stock rising over 6% and WuXi Biologics increasing by more than 5% [3] - Overall, the CRO index in A-shares saw an increase of over 5% as of January 13 [3] Group 3 - WuXi AppTec has raised its revenue forecast for the previous year for the third time, while WuXi Biologics expressed confidence in maintaining growth momentum through 2026 [4][5] - CITIC Securities published a report indicating optimism regarding Chinese companies' technological breakthroughs and international opportunities, highlighting a shift from a single market focus to global value creation [6] - Chinese pharmaceutical companies are becoming key players in global pharmaceutical innovation, leveraging a dual strategy of independent research and overseas business development [6]